Navigation Links
Amira Pharmaceuticals Hires Industry Veteran for CFO Position
Date:6/9/2008

SAN DIEGO, June 9 /PRNewswire/ -- Amira Pharmaceuticals, a small molecule pharmaceutical company focused on the discovery and development of compounds to treat inflammatory diseases, announced the hiring of Michael V. Swanson as the company's Chief Financial Officer.

Swanson has over 30 years of experience in finance and accounting, including 17 years of CFO-level experience in life sciences and specialty pharmaceutical companies. Prior to joining Amira, Swanson was the CFO of Prometheus Laboratories Inc., a privately-held specialty pharmaceutical company which sells both pharmaceutical products and diagnostic testing services for gastrointestinal diseases and disorders. During his time at Prometheus, Swanson led several financings totaling over $200 million dollars and, most recently, led the filing of a registration statement for Prometheus' initial public offering. Prior to Prometheus, Swanson was the CFO of Advanced Tissue Sciences, Inc. where his responsibilities included the financing of this publicly-held, life sciences company. Swanson is a Certified Public Accountant and holds an MBA from the University of Southern California.

"Mike's track record in the pharmaceutical industry speaks for itself, and I look forward to partnering closely with him as we chart a course for the company. His addition further enriches an already diverse and strong management team," said Bob Baltera, Chief Executive Officer, Amira.

"I am truly excited to be working with the proven group of drug hunters at Amira," said Swanson. "I believe I will be able to provide the financial expertise and support required on this fascinating journey of drug discovery and development."

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of compounds to treat inflammatory disease linked to the eicosanoid pathway. Amira has strategic partnerships with GlaxoSmithKline and Roche in the area of inflammatory disease.

Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair(R). The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future. For more information, visit http://www.amirapharm.com.


'/>"/>
SOURCE Amira Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter
2. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
3. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
4. Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
5. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
6. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
7. Onyx Pharmaceuticals to Present at Goldman Sachs 29th Annual Global Healthcare Conference
8. Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
9. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
10. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
11. Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Cancer experts from Austria, Hungary, Switzerland, and ... new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just published ... , Biomarkers are components in the blood, tissue or body fluids that ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
Breaking Biology Technology:
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, Biometrics & ... & Other Service  The latest report from ... of the global Border Security market . Visiongain ... billion in 2016. Now: In November 2015 ... and hardware technologies for advanced video surveillance. ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
Breaking Biology News(10 mins):